<div class="article">
	<h3>Financing Business:
   Lidak Pharmaceuticals</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 05/16/90</li>
		</ul>
	</div>
	<p class="article-leader">LIDAK PHARMACEUTICALS said it completed its initial public
offering of one million units at $5 each. Each unit consists
of five common shares and five redeemable Class A warrants.
Each Class A warrant is exercisable to buy one common share
and one redeemable Class B warrant at $1.50 until May 8,
1995. Each Class B warrant holder may buy one common share at
$2.25 until May 8, 1995. D.H. Blair & Co. managed the
underwriters, the La Jolla, Calif., company said. Proceeds
will be used to fund human clinical trials of a therapeutic
product to treat herpes and certain inflammatory skin
disorders and for research and development of other
pharmaceutical products.</p>
	<div class="article-body"><p></p></div>
</div>
